UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues
about
Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyPharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Magnetic resonance imaging of folic acid-coated magnetite nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapyPharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized miceMononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapyPharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapyMacrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infectionsSmall magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution.Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain.Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.
P2860
Q28551873-87947D5B-4AFB-4FF5-B420-6DF6ACE1158DQ30603781-3182132A-7FDC-41EC-AF1A-31D61FB9F02DQ33625213-FE3134A0-79BE-4723-878A-FB8C3009DDD3Q34745586-62C58888-2D0A-4505-8931-6396E14842B7Q35703450-617ADD2A-D048-4520-8233-8E6A90AC36F4Q35822619-BEFF2C60-38D1-42E7-8BB9-E65B03A25651Q35979166-7C084CEB-1E65-4EF2-9EB8-B31CA97D5D0AQ36505647-B875B34D-F901-47CE-8716-2DE6E65820F7Q36603756-CFE4AD12-AA49-4E83-930D-5B38B10A60BEQ36969787-733C32A5-F2AF-40B6-84B9-31BB9FB20A23Q37188867-D0CCC626-F694-4853-A2EA-27598C0A262CQ41905223-072BF08B-3D19-4261-BE05-2A3E1CB11DBFQ46448056-D0631FAB-B48D-45C8-A022-1EB071CE1A3BQ47548818-CC916506-71E7-484B-9557-9C45EA6B4577Q51848081-6F4714B0-E593-49D4-96C6-15DD97F5B978Q54267469-753A8351-25D0-4BE8-9EE8-3D432A070680
P2860
UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
UPLC-MS/MS quantification of n ...... enz in mouse serum and tissues
@en
UPLC-MS/MS quantification of n ...... enz in mouse serum and tissues
@nl
type
label
UPLC-MS/MS quantification of n ...... enz in mouse serum and tissues
@en
UPLC-MS/MS quantification of n ...... enz in mouse serum and tissues
@nl
prefLabel
UPLC-MS/MS quantification of n ...... enz in mouse serum and tissues
@en
UPLC-MS/MS quantification of n ...... enz in mouse serum and tissues
@nl
P2093
P2860
P1476
UPLC-MS/MS quantification of n ...... enz in mouse serum and tissues
@en
P2093
Howard E Gendelman
Jiangeng Huang
JoEllyn McMillan
Nagsen Gautam
Sai Praneeth R Bathena
Yazen Alnouti
P2860
P304
P356
10.1016/J.JCHROMB.2011.06.032
P577
2011-07-01T00:00:00Z